ID: 615 | Pages: 132 | October 2016 | Region: Latin America
The Latin America Colorectal Cancer Market was worth $1.27 billion in 2016 and estimated to be growing at a CAGR of 2.10%, to reach $1.41 billion by 2021. Though there has been substantial development in science and technology to combat cancer, it continues to threaten lives across the globe.
Colorectal cancer is identified with a biopsy, which then followed by medical imaging to know its extent. Depending on the stage and how much the cancer has expanded, a combination of radiation therapy, chemotherapy, and targeted therapy is recommended by most oncologists.
The growth of the Latin America Colorectal Cancer Market is mainly driven by factors such as rise in aging population, and government policies to provide better care for Colorectal Cancer. However, factors such as high costs of screening tests and poor accessibility of proper health care in this part of the world are hindering the growth of the market.
The Latin America Colorectal Cancer market is segmented based on Diagnosis and Treatment. The market for Colorectal Cancer, on the basis of Diagnosis is segmented into Digital Rectal Examination, Faecal Occult Blood Test, Flexible Sigmoidoscopy, Colonoscopy, Virtual Colonoscopy. On the basis of Treatment, the global Colorectal Cancer market is segmented into Surgery and Radiation Therapy, Chemotherapy, Targeted Therapies, Resistance to Pharmacological Therapies.
Latin America market region includes countries such as Brazil, Mexico, Argentina, and remaining countries of South America. Brazil accounts for the major part of the Colorectal Cancer market in this region followed by Argentina. Other significant markets in this region are Uruguay, Paraguay, Colombia, Chile, and Bolivia.
Some of the major companies dominating this market are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, Hoffmann La Roche, Debiopharm Group, Vaccinogen BD.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Diagnosis
5.1.1 Digital Rectal Examination
5.1.2 Faecal Occult Blood Test
5.1.3 Flexible Sigmoidoscopy
5.1.4 Colonoscopy
5.1.5 Virtual Colonoscopy
5.2 By Treatment
5.2.1 Surgery and Radiation Therapy
5.2.2 Chemotherapy
5.2.3 Targeted Therapies
5.2.4 Resistance to Pharmacological Therapies
6. Geographical Analysis
6.1 Introduction
6.2 Brazil
6.3 Argentina
6.4 Mexico
6.5 Rest of Latin America
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Diagnostics
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Alere
8.3 Beckman Coulter
8.4 Clinical Genomics
8.5 Companion Dx
8.6 Hoffmann La Roche
8.7 Debiopharm Group
8.8 Vaccinogen BD
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Title | Price | Add To Cart |
© 2018 Market Data Forecast
All Rights Reserved.